Incyte (NASDAQ:INCY) Cut to “Market Perform” at William Blair

William Blair lowered shares of Incyte (NASDAQ:INCY) from an outperform rating to a market perform rating in a research report released on Tuesday, MarketBeat Ratings reports. William Blair also issued estimates for Incyte’s Q2 2025 earnings at $1.11 EPS, Q3 2025 earnings at $1.19 EPS, FY2025 earnings at $4.21 EPS and Q3 2026 earnings at $1.30 EPS.

A number of other research firms have also recently weighed in on INCY. Royal Bank of Canada lowered their target price on shares of Incyte from $70.00 to $68.00 and set a “sector perform” rating on the stock in a research note on Tuesday, February 11th. StockNews.com lowered Incyte from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 12th. UBS Group initiated coverage on Incyte in a research report on Tuesday, December 17th. They set a “neutral” rating and a $77.00 target price for the company. JMP Securities reiterated a “market perform” rating on shares of Incyte in a research report on Tuesday, February 11th. Finally, Wells Fargo & Company increased their price objective on Incyte from $68.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Thursday, December 19th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $75.13.

Incyte Price Performance

Shares of INCY stock opened at $60.58 on Tuesday. Incyte has a 12 month low of $50.35 and a 12 month high of $83.95. The company has a market capitalization of $11.72 billion, a P/E ratio of 224.38, a P/E/G ratio of 0.41 and a beta of 0.76. The stock has a 50 day moving average of $70.78 and a two-hundred day moving average of $70.13. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last issued its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. As a group, equities analysts expect that Incyte will post 4.86 EPS for the current year.

Insider Transactions at Incyte

In other Incyte news, EVP Steven H. Stein sold 12,352 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total transaction of $897,866.88. Following the transaction, the executive vice president now directly owns 66,967 shares in the company, valued at approximately $4,867,831.23. This represents a 15.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Barry P. Flannelly sold 19,807 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the completion of the transaction, the executive vice president now directly owns 33,567 shares in the company, valued at $2,272,150.23. This trade represents a 37.11 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,827 shares of company stock worth $3,322,618. Corporate insiders own 17.60% of the company’s stock.

Hedge Funds Weigh In On Incyte

Several large investors have recently bought and sold shares of the business. CWA Asset Management Group LLC bought a new position in Incyte during the fourth quarter worth about $1,933,000. Orion Portfolio Solutions LLC acquired a new stake in shares of Incyte in the 3rd quarter valued at approximately $770,000. Tri Ri Asset Management Corp bought a new position in Incyte during the 3rd quarter worth approximately $3,292,000. Cypress Capital Group acquired a new position in Incyte during the third quarter valued at approximately $971,000. Finally, Bridgewater Associates LP grew its holdings in Incyte by 142.8% during the third quarter. Bridgewater Associates LP now owns 308,632 shares of the biopharmaceutical company’s stock valued at $20,401,000 after purchasing an additional 181,504 shares during the period. 96.97% of the stock is currently owned by institutional investors and hedge funds.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.